Update on Russia Trials
Applied Clinical Trials
A recently released report details the current status of the clinical trials market in Russia.
A recently released report details the current status of the clinical trials market in Russia. According to the Russian CRO Synergy Research Group, the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 130 new clinical trials in Russia in first quarter 2008; that's four trials less than in the corresponding period last year.
The report noted that the main contribution is still made by multinational, multicenter clinical trials. The share of foreign study sponsors in first quarter 2008 stood at 68% of the total number of clinical trials, and 88 new trials were initiated during this period. To read the report from Synergy Research Group, go to www.synrgpharm.com/images/SynRG_Orange_Paper_2008Q1_E.pdf.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
